OVERVIEW

Originally developed for type 2 diabetes management, Tirzepatide has demonstrated additional benefits, including cardiovascular protection and effective weight loss support. This synthetic peptide is derived from gastric inhibitory polypeptide (GIP) while also acting as a glucagon-like peptide-1 (GLP-1) receptor agonist, allowing it to:

• Regulate blood sugar levels
• Enhance insulin sensitivity
• Promote satiety
• Facilitate weight loss

RESEARCH

Tirzepatide is a synthetic analogue of gastric inhibitory polypeptide (GIP), designed to stimulate insulin release and support the management of type 2 diabetes and non-alcoholic fatty liver disease. Composed of 39 amino acids, this peptide functions by activating both GIP and GLP-1 receptors, leading to improved insulin regulation and metabolic balance.

Long-term use of Tirzepatide has been shown to increase adiponectin levels by up to 26%, contributing to:

• Reduced hunger and cravings
• Lower fasting insulin levels
• Greater insulin sensitivity

These metabolic effects result in:

• Significant weight loss (approximately 11 kg or 25 lbs)
• Enhanced glucose control
• Decreased fat storage
• Lower cardiovascular risk factors

STRUCTURE

• Amino Acid Sequence: YE-Aib-GTFTSDYSI-Aib-LDKIAQ AFVQWLIAGGPSSGAPPPS
  (Aib is a non-standard amino acid: H H-C(CH3)COOH)
• Molecular Formula: C₂₂₅H₃₄₈N₄₈O₆₈
• Molecular Weight: 4813.527 g/mol
• PubChem Identifier: 156588324
• CAS Registry Number: 2023788-19-2
• Alternative Names: P1206, LY3298176

CITATIONS

Source: PubChem